目的探讨术前多帕菲联合卡铂化疗对巨块型宫颈癌的疗效及安全性。方法选择病理确诊的35例Ⅰb～Ⅱb期巨块型宫颈癌患者,术前行多帕菲+卡铂化疗2个疗程,化疗后行宫颈癌根治术。结果新辅助化疗临床有效率达91.42%,手术切除率100%。结论术前多帕菲联合卡铂化疗可使Ⅰb～Ⅱb期巨型宫颈癌临床分期降低,提高手术成功率。
宫颈癌为妇科常见的恶性肿瘤之一,宫颈癌的标准治疗目前以手术和放疗为主,肿瘤较大的宫颈癌患者手术有一定困难,且术后复发率高。近年来,对肿块直径>4cm的宫颈癌患者提出了新辅助化疗方案(neoadjuvant chemoth erapy,NACT)即先行化疗缩小病灶范围,再行根治术[1]。

[Objective] To observe the efficacy and safety on treating bulky cervical cancer with Dopafei and Carboplatin before operation. [Methods] 35 cases of Ⅰb～Ⅱb period bulky cervical cancer were treated by untied chemotherapy of Dopafei and Carboplatin during two cycles before operation, after chemotherapy they were treated by radical hysterectomy. [Results] After the neoadjuvant chemotherapy (NACT), the therapeutic effective rate can obtain 91.42%, and all of sufferers can be treated by operation. [Conclusions] Clinical staging of Ⅰ b～Ⅱb period bulky cervical cancer can be depressed by untied chemotherapy of Dopafei and Carboplatin before operation, at the same time, the the successful rate of operation can be raised.